Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study
Top Cited Papers
- 1 November 2014
- journal article
- research article
- Published by Elsevier BV in The Lancet Respiratory Medicine
- Vol. 2 (11), 879-890
- https://doi.org/10.1016/s2213-2600(14)70201-2
Abstract
No abstract availableKeywords
Funding Information
- MedImmune
This publication has 33 references indexed in Scilit:
- Anti-interleukin-5 therapy in severe asthmaEuropean Respiratory Review, 2013
- A Large Subgroup of Mild-to-Moderate Asthma Is Persistently NoneosinophilicAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Variability of sputum inflammatory cells in asthmatic patients receiving corticosteroid therapy: A prospective study using multiple samplesJournal of Allergy and Clinical Immunology, 2010
- Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbationsInternational Journal of Clinical Practice, 2007
- Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research ProgramJournal of Allergy and Clinical Immunology, 2007
- Eosinophilic Airway DisordersSeminars in Respiratory and Critical Care Medicine, 2006
- Identifying ‘well-controlled’ and ‘not well-controlled’ asthma using the Asthma Control QuestionnaireRespiratory Medicine, 2006
- General considerations for lung function testingEuropean Respiratory Journal, 2005
- Measurement properties and interpretation of three shortened versions of the asthma control questionnaireRespiratory Medicine, 2005
- Development and validation of a questionnaire to measure asthma controlEuropean Respiratory Journal, 1999